Sarepta shares sink as FDA staff stay sour on muscle disorder drug

(Reuters) - Sarepta Therapeutics Inc lost more than a third of its market value after U.S. Food and Administration staff maintained their negative outlook on the company's rare muscle wasting disorder drug on Thursday.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro